Andecaliximab (Anti-MMP9) is a recombinant chimeric IgG4 monoclonal antibody (mAb) that targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. MW: 145.5 kD.